clinical trial

Celcuity stock rises over 4% after beating loss expectations and securing $166M cash position, with phase 3 trial results anticipated in Q2.

Grail stock jumped 11.4% as Wall Street analysts see upside in its cancer detection test despite February trial disappointment.

Portnoy Law Firm sues Soleno Therapeutics for allegedly concealing DCCR safety risks in Phase 3 trials, citing 27% stock drop on November 4, 2025.

Soligenix's dusquetide (SGX945) receives EU orphan drug designation for Behçet's Disease, backed by Phase 2a data showing 40% ulcer reduction with no adverse events.

Securities lawsuit alleges $SLNO concealed safety concerns about DCCR, its only commercial product for Prader-Willi syndrome treatment, ahead of May 5, 2026 lead plaintiff deadline.

IceCure Medical reports positive 5-year results from ICESECRET trial, demonstrating 83.9% recurrence-free rates in kidney cancer patients using cryoablation technology.

Beam Therapeutics reports positive Phase 1/2 data for BEAM-302 base editing therapy in alpha-1 antitrypsin deficiency, advancing toward pivotal development in late 2026.

Merck acquires Terns Pharmaceuticals for $6.7 billion to gain TERN-701, a novel leukemia treatment, at 31% premium valuation.

Soleno Therapeutics faces securities lawsuit alleging undisclosed safety risks in its sole commercial product DCCR. Investors have until May 5, 2026 to seek lead plaintiff status.

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

Law firm Bernstein Liebhard files securities fraud class action against $SLNO, citing alleged misrepresentations regarding Phase 3 DCCR clinical trial program.

Aethlon Medical's Hemopurifier device advances to final clinical trial phase following positive safety review with no adverse events reported.

Sanofi and Regeneron's Dupixent secured Japanese regulatory approval for bullous pemphigoid, marking the drug's seventh indication in Japan with superior remission rates versus placebo.

Dupixent receives Japanese marketing authorization for bullous pemphigoid, becoming the first targeted treatment. Study showed 18% remission rate versus 4% for placebo.

Class action lawsuit filed against $SLNO alleging failure to disclose safety concerns about DCCR drug candidate, including fluid retention issues in clinical trials.

$SLNO investors urged to join class action over undisclosed DCCR safety concerns; May 5, 2026 deadline.

RTW Investments purchases $116M stake in Cogent Biosciences, raising position to 2.7% of AUM amid 360% stock surge and anticipated 2026 FDA decision on lead drug.

Bristol Myers wins FDA approval for Opdivo plus chemotherapy in untreated Hodgkin lymphoma. Stock declined 1.33% despite clinical success in Study CA209-8UT.

Novo Nordisk wins FDA approval for Wegovy HD, a higher-dose version launching in April across 70,000+ U.S. pharmacies, despite modest stock decline.

Class action lawsuit filed against REGENXBIO alleging false statements about RGX-111 gene therapy development and clinical trials, covering investors from February 2022 through January 2026.